Novel Therapeutics in Sjögren's Disease: A Systematic Literature Review
Keywords:
Sjögren's syndrome, novel therapeutics, biologics, systematic review, CD40, disease duration, efficacy, safetyAbstract
Introduction: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with significant morbidity and unmet therapeutic needs. Current treatments are largely palliative. This systematic review synthesizes evidence on novel biologic and immunomodulatory therapies aimed at disease modification.
Methods: A systematic search was conducted across multiple databases (PubMed, Semantic Scholar, Springer, etc.) for studies (RCTs, systematic reviews) evaluating novel therapeutics (biologics, immunomodulators) in pSS patients. Data on therapy, population, design, efficacy (ESSDAI, ESSPRI, glandular function), and safety were extracted.
Results: Thirty-two studies were included. Agents targeting the CD40/CD40L pathway (iscalimab, dazodalibep) and FcRn (nipocalimab) demonstrated statistically significant and clinically meaningful improvements in systemic disease activity (ESSDAI) and patient-reported symptoms (ESSPRI). In contrast, abatacept, tocilizumab, and JAK/SYK/BTK inhibitors showed limited efficacy. A critical finding was that patients with early disease (≤3 years duration) responded significantly better to biologics. Safety analysis confirmed a higher risk of serious adverse events with biological therapies, though profiles varied by drug class. Glandular function improvements were modest overall but more pronounced with regenerative approaches like stem cell therapy.
Discussion: The CD40/CD40L pathway is a validated, high-priority therapeutic target in pSS. Disease duration is a key modifier of treatment response, highlighting a therapeutic window for early intervention. Heterogeneity in trial results is explained by factors including disease duration, dosing, and outcome measurement sensitivity.
Conclusion: This review establishes a hierarchy of efficacy, with CD40/CD40L and FcRn blockade as the most promising strategies. Early intervention is crucial for optimal outcomes. Future research must focus on trials in early disease, predictive biomarkers, long-term safety, and regenerative therapies.
References
A. Baer, J. Gottenberg, E. S. St Clair, T. Sumida, T. Takeuchi, R. Seror, G. Foulks, et al. “Efficacy and Safety of Abatacept in Active Primary Sjögren’s Syndrome: Results of a Phase III, Randomised, Placebo-Controlled Trial.” Annals of the Rheumatic Diseases, 2020.
B. Fisher, A. Szántó, M. Rischmueller, T. Varga, A. Kleyer, S. Finzel, J. A. Garcia Meijide, et al. “POS0375 ASSESSMENT OF S95011 (OSE-127, LUSVERTIKIMAB), AN ANTI-INTERLEUKIN 7 RECEPTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: AN INTERNATIONAL MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY.” Scientific Abstracts, 2024.
B. Fisher, A. Szántó, W. Ng, M. Bombardieri, M. Posch, A. Papas, A. Farag, et al. “Assessment of the Anti-CD40 Antibody Iscalimab in Patients with Primary Sjögren's Syndrome: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study.” The Lancet Rheumatology, 2020.
E. Pontarini, F. Chowdhury, E. Sciacca, S. Grigoriadou, W. Murray-Brown, F. Rivellese, D. Lucchesi, et al. “POS0145 CLINICAL RESPONSE TO RITUXIMAB IS ASSOCIATED WITH PREVENTION OF B-CELL DRIVEN SALIVARY GLAND INFLAMMATION AND EPITHELIAL RESTORATION AS REVEALED BY MOLECULAR PATHOLOGY: RESULTS FROM THE TRACTISS TRIAL IN PRIMARY SJOGREN’S SYNDROME.” Annals of the Rheumatic Diseases, 2022.
E. Price, M. Bombardieri, A. Kivitz, F. Matzkies, O. Gurtovaya, A. Pechonkina, Wendy Jiang, et al. “Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Sjögren’s Syndrome: A Randomized, Phase 2, Double-Blind, Placebo-Controlled Study.” Rheumatology, 2022.
E. S. St Clair, I. Alevizos, W. Rees, L. Wang, A. Baer, W. Ng, G. Noaiseh, and C. Baldini. “LB0003 Dazodalibep (VIB4920/HZN4920) in Sjögren’s Subjects with an Unacceptable Symptom Burden: Safety and Efficacy from a Phase 2, Randomized, Double-Blind Study.” Annals of the Rheumatic Diseases, 2023.
E. William, St. Clair, Alan N Baer, W. Ng, G. Noaiseh, Chiara Baldini, Teresa K Tarrant, et al. “CD40 Ligand Antagonist Dazodalibep in Sjögren’s Disease: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Trial.” Nature Network Boston, 2024.
Fangfang Li, Junhui Lu, Xinlian Shi, Dong-yan Li, Tingting Zhou, Tian-xiu Jiang, and Sheng-Shih Wang. “Effect of Adipose Tissue-Derived Stem Cells Therapy on Clinical Response in Patients with Primary Sjogren’s Syndrome.” Scientific Reports, 2023.
Francine Bertolais do Valle Souza, G. Porfírio, B. Andriolo, J.V. de Albuquerque, and V. Trevisani. “Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis.” PLoS ONE, 2016.
G. Verstappen, H. Bootsma, S. Finzel, A. Grioni, B. Fisher, A. Papas, C. Rauld, et al. “OP0040 DOSE DEPENDENT MODULATION OF PROTEOMIC SIGNATURES BY IANALUMAB IN PATIENTS WITH SJÖGREN’S DISEASE.” Scientific Abstracts, 2024.
Hind Letaief, C. Lukas, T. Barnetche, C. Gaujoux-Viala, B. Combe, and J. Morel. “Efficacy and Safety of Biological DMARDs Modulating B Cells in Primary Sjögren's Syndrome: Systematic Review and Meta-Analysis.” Joint, Bone, Spine : Revue Du Rhumatisme, 2018.
J. Clarke. “International Classification Criteria Created for IgG4-Related Disease.” Nature Reviews Rheumatology, 2020.
———. “Long-Term Safety of Ixekizumab Confirmed in PsA.” Nature Reviews Rheumatology, 2020.
J. V. van Nimwegen, E. Mossel, G. V. van Zuiden, Robin F. Wijnsma, K. Delli, A. Stel, B. van der Vegt, et al. “Abatacept Treatment for Patients with Early Active Primary Sjögren's Syndrome: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial (ASAP-III Study).” The Lancet Rheumatology, 2020.
Jennifer A. Thorley. “Research in Brief.” The Lancet Rheumatology, 2022.
Jincheng Pu, Xuan Wang, F. Riaz, Tongyangzi Zhang, Ronglin Gao, Shengnan Pan, Zhenzhen Wu, Yuanyuan Liang, Shuqi Zhuang, and Jianping Tang. “Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis.” Frontiers in Pharmacology, 2021.
Jing He, Jiali Chen, M. Miao, Ruijun Zhang, Gong Cheng, Yifan Wang, Ruiling Feng, et al. “Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome.” JAMA Network Open, 2022.
L. Chu, K. Cui, and J. Pope. “FRI0324 Immunosuppression for Primary Sjogren’s Syndrome: A Systematic Review and Meta-Analysis.” FRIDAY, 15 JUNE 2018, 2018.
L. Gueiros, Katherine France, Rachael Posey, J. Mays, Barbara Carey, T. Sollecito, Fds RCSEd, et al. “WWOM VII: Immunobiologics for Salivary Gland Disease in Sjögren’s Syndrome: A Systematic Review,” 2019.
Liuting Zeng, Qi-Qi He, Kailin Yang, Wensa Hao, Ganpeng Yu, and Hua Chen. “A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome.” Frontiers in Immunology, 2022.
Luiz Alcino, Dds MSc Gueiros, Dmd Mbe Katherine France, Rachael Posey Msls, MHSc Jacqueline W. Mays DDS, MB Bds Barbara Carey, D. F. Thomas P Sollecito, et al. “WWOM VII: Immunobiologics for Salivary Gland Disease in Sjögren’s Syndrome: A Systematic Review,” 2019.
M. Møller-Hansen, Ann‐Cathrine Larsen, A. Wiencke, L. Terslev, Volkert Siersma, Tobias T. Andersen, A. E. Hansen, et al. “Allogeneic Mesenchymal Stem Cell Therapy for Dry Eye Disease in Patients with Sjögren's Syndrome: A Randomized Clinical Trial.” The Ocular Surface, 2023.
R. Felten, V. Devauchelle-Pensec, R. Seror, P. Duffau, D. Saadoun, E. Hachulla, Hatron Pierre Yves, et al. “Interleukin 6 Receptor Inhibition in Primary Sjögren Syndrome: A Multicentre Double-Blind Randomised Placebo-Controlled Trial.” Annals of the Rheumatic Diseases, 2020.
S. Bowman, R. Fox, T. Dörner, X. Mariette, A. Papas, T. Grader-Beck, B. Fisher, et al. “Safety and Efficacy of Subcutaneous Ianalumab (VAY736) in Patients with Primary Sjögren's Syndrome: A Randomised, Double-Blind, Placebo-Controlled, Phase 2b Dose-Finding Trial.” The Lancet, 2021.
Sarah R Brown, N. Navarro Coy, C. Pitzalis, P. Emery, S. Pavitt, J. Gray, C. Hulme, et al. “The TRACTISS Protocol: A Randomised Double Blind Placebo Controlled Clinical TRial of Anti-B-Cell Therapy In Patients with Primary Sjögren’s Syndrome.” BMC Musculoskeletal Disorders, 2014.
Susanne Kammerer. “Nipocalimab Meets Primary Endpoint in Sjögren’s Syndrome.” Medicom Conference Report EULAR 2024, 2024.
T. Dörner, M. Posch, Yue Li, O. Pétricoul, M. Cabański, J. Milojevic, E. Kamphausen, et al. “Treatment of Primary Sjögren’s Syndrome with Ianalumab (VAY736) Targeting B Cells by BAFF Receptor Blockade Coupled with Enhanced, Antibody-Dependent Cellular Cytotoxicity.” Annals of the Rheumatic Diseases, 2019.
Thomas Dörner, M. Zeher, U. Laessing, F. Chaperon, S. D. Buck, A. Hasselberg, Marie-Anne Valentin, et al. “OP0250 A Randomised, Double-Blind Study to Assess the Safety, Tolerability and Preliminary Efficacy of Leniolisib (CDZ173) in Patients with Primary sjÖgren’s Syndrome.” FRIDAY, 15 JUNE 2018, 2018.
V. Devauchelle-Pensec, X. Mariette, S. Jousse-Joulin, J. Berthelot, A. Perdriger, E. Hachulla, X. Puéchal, et al. “OP0065 Tolerance and Efficacy of Rituximab in Primary Sjogren Syndrome (TEARS): Results of a Randomized Controlled Trial,” 2013.
V. Devauchelle-pensec, X. Mariette, S. Jousse-Joulin, J. Berthelot, A. Perdriger, Xavier Puchal, Vronique Le Guern, et al. “Treatment of Primary Sjgren Syndrome With Rituximab.” Annals of Internal Medicine, 2014.
Weiguo Bai, Fan Yang, Huji Xu, Wei Wei, Hongbin Li, Liyun Zhang, Yi Zhao, et al. “A Multi-Center, Open-Label, Randomized Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren’s Syndrome Patients.” Trials, 2023.
Xiaoyan Wang, Xiang Lin, Yingying Su, and Hao Wang. “Systematic Review with Meta-Analysis: Efficacy and Safety of Biological Treatment on Salivary Gland Function in Primary Sjögren’s Syndrome.” Frontiers in Pharmacology, 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Bernie (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
